RET and non-small cell lung carcinoma: A timely example of the importance of expanded molecular testing in NSCLC are the recent FDA approvals of the specific RET inhibitors selpercatinib and pralsetinib which have resulted in a requirement to test for RET gene fusions in lung cancer, and activating point mutations in medullary thyroid cancer (3–7).